The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial

Start Date01 Dec 2026

Sponsor / Collaborator

Queen Mary University of London

NCT05900388

/ Not yet recruitingNot Applicable

Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.
Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.
The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.
The main information that researchers will collect in this study:
* Age, gender, and other information about the child and their illness
* Type of VTE treatment given to the child
* Occurrence of medically important bleeding and its severity
Further information that researchers will collect:
* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
* Return of VTE symptoms
* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.
The data for this study will be collected from electronic health records and health insurance claims data until 2026.
Researchers will observe each child during treatment until:
* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
* their information is no longer available, or
* the study ends.

Start Date01 Sep 2026

Sponsor / Collaborator

Bayer AG

[+1]

NCT06396858

/ Not yet recruitingPhase 4IIT

A 2 x 2 Factorial Randomized Clinical Trial Evaluating Anti-inflammatory and Anti-thrombotic Strategy in Acute Ischemic Stroke

The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.

Start Date01 Jul 2026

Sponsor / Collaborator-

100 Clinical Results associated with Rivaroxaban

100 Translational Medicine associated with Rivaroxaban

100 Patents (Medical) associated with Rivaroxaban

8,611

Literatures (Medical) associated with Rivaroxaban

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany

Article

Author: Dworatzek, Elke ; Duan, Cecilia ; Kongnakorn, Thitima ; Zhang, Michelle ; Hines, Dionne M. ; Kisser, Agnes ; Subash, Rupesh

01 Jun 2026·AMERICAN HEART JOURNAL

STrategies for antithrombotic tRreatment following transcatheter edge-to-edge repair in patients with severe mitral regurgitation: Rationale and design of STAR-TEER trial

Article

Author: Yan, Xiaofang ; Wang, Cheng ; Wang, Chuangshi ; Ma, Jianrui ; Zhou, Ning ; Zhang, Fengwen ; Li, Ziping ; Ouyang, Wenbin ; Zhao, Guangzhi ; Liu, Zizheng ; Pan, Xiangbin ; Wang, Shouzheng

BACKGROUND:

Transcatheter edge-to-edge repair (TEER) has emerged as an important therapy for severe mitral regurgitation. Current guidelines lack evidence-based recommendations for optimal postprocedural antithrombotic strategies, leading to heterogeneous clinical practices. And there are no randomized controlled trials (RCTs) available to compare different antithrombotic strategies following TEER.

METHODS:

STAR-TEER trial is an investigator-initiated, multicenter, randomized, parallel controlled, open-label trial, aiming to assess the safety and efficacy of de-escalated antithrombotic strategies with monotherapy in post-TEER patients with or without indications for oral anticoagulation (OAC) respectively. This trial plans to enroll 1,912 patients stratified into 2 cohorts: patients in Cohort A (requiring long-term OAC, n = 880) will be randomized 1:1 to rivaroxaban monotherapy or rivaroxaban plus clopidogrel, and patients in Cohort B (no OAC indication, n = 1,032) will be randomized 1:1 to aspirin monotherapy or aspirin plus clopidogrel. The primary outcome is all bleeding complications within 12 months post-TEER. The 2 key secondary outcomes are nonprocedure-related bleeding within 12 months post-TEER (key secondary outcome 1) and a composite of ischemic events including all-cause mortality, stroke, systemic embolism, and myocardial infarction within 12 months post-TEER (key secondary outcome 2). A hierarchical hypothesis testing will be performed, with the primary outcome and key secondary outcome 1 tested for superiority, followed by the key secondary outcome 2 tested for noninferiority.

CONCLUSION:

The STAR-TEER trial is the first large randomized controlled trial (RCT) to stratify patients based on OAC indication and compare different antithrombotic strategies following TEER in these 2 distinct cohorts.

TRIAL REGISTRATION:

URL: https://www.

CLINICALTRIALS:

gov. Unique identifier: NCT06901466 (Cohort A), NCT07007143 (Cohort B).

01 Apr 2026·Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Proposal for a tooth extraction protocol for patients taking direct oral anticoagulants: a clinical trial

Article

Author: Paiva, Gustavo Luiz Alkmin ; Omori, Vitor Takao ; Scanavacca, Maurício Ibraim ; Neves, Itamara Lucia Itagiba ; Darrieux, Francisco Carlos da Costa ; Alves Dos Santos Paul, Marcela ; Higashi, Elaine Massumi ; Hachul, Denise Tessariol ; Simões Neves, Ricardo

OBJECTIVE:

To evaluate the feasibility of a protocol in which direct oral anticoagulants (DOACs) are not discontinued prior to tooth extractions, compared with warfarin.

STUDY DESIGN:

A prospective blind study was conducted on anticoagulated patients with atrial fibrillation undergoing tooth extraction. Patients were divided into three groups according to the anticoagulant pharmacokinetics: 20 patients on rivaroxaban once daily; 18 on dabigatran or apixaban twice daily, and 20 on warfarin (control group). Extractions were scheduled during the lowest DOACs plasma concentration: 14 hours after the last rivaroxaban dose; 8 hours after the last dabigatran/apixaban dose; and with INR values between 2.0 and 3.0 in the warfarin group. Patients returned 24 hours after tooth extraction for evaluation of bleeding.

RESULTS:

Fifty-eight patients were included in the study, in a total of 84 tooth extractions. No minor or major bleeding occurred in the rivaroxaban group. Two patients in the dabigatran/apixaban group (11.1%) and two in the control group (10%) presented minor bleeding. There was no statistically significant difference in bleeding rates among the groups (P = .324), and no major bleeding events were reported.

CONCLUSION:

These preliminary results suggest that the protocol proposing non-discontinuing DOACs in extractions may be feasible in clinical practice.

351

News (Medical) associated with Rivaroxaban

19 Mar 2026

·www.prnewswire.com

CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026

PRINCETON, N.J., March 19, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced three major developments at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) this week in Brussels, Belgium - one of the largest global conferences dedicated to critical care medicine: The introduction of HotSwap™ by CytoSorbents – The New CytoSorb exchange system The renewal of its long-standing partnership with Aferetica Srl in Italy, and New clinical data reinforcing the growing body of evidence supporting CytoSorb® therapy CytoSorbents Launches HotSwap™ to Simplify and Optimize Therapy CytoSorbents announced the immediate availability of HotSwap™, an innovative solution designed to enable rapid, seamless exchange of CytoSorb adsorbers during the treatment of critically-ill patients. HotSwap™ is designed to: Enable faster, easier device exchanges – particularly in high-acuity patients requiring frequent changes Facilitate the safe return of blood from used devices back to the patient Streamline workflows for ICU staff, reducing nursing burden and improving treatment consistency "In critically ill patients, timing, dosing, and treatment intensity are essential to improving outcomes," stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. "HotS clinicians to more easily and efficiently treat the right patient, at the right time, with the right dose. Early user feedback has been highly positive, reinforcing our decision to make this technology broadly available." Dr. Chan added, "In life-threatening diseases such as sepsis, acute respiratory distress syndrome, liver failure, and trauma, unstable patients often require multiple device changes per day in the early phase of treatment to control deadly massive inflammation or to reduce high concentrations of toxic substances that can otherwise lead to organ failure and death. HotS this process faster, safer, and more practical, while preserving valuable blood volume and reducing the workload on ICU teams." CytoSorbents Renews Strategic Partnership with Aferetica CytoSorbents also announced the renewal of its exclusive distribution agreement with Aferetica Srl in Italy, extending a successful collaboration spanning more than a decade. The partnership has supported widespread adoption of CytoSorb across critical care and cardiac surgery in Italy. The companies have also collaborated on Aferetica's innovative PerLife® organ perfusion platform, which integrates CytoSorbents' PerSorb® cartridge to improve organ preservation and rehabilitation for transplantation. "Aferetica has been an exceptional long-term partner," stated Dr. Chan. "CEO Mauro Atti and his team, working closely with leading clinicians and researchers in the country, have played a critical role in advancing both the clinical adoption and scientific understanding of CytoSorb therapy. We are excited to continue working together to expand innovation in blood purification and organ transplantation." Mr. Mauro Atti, Chief Executive Officer of Aferetica SRL stated, "We are happy to continue our successful collaboration with CytoSorbents that has contributed to the growth of our companies and importantly, the care and recovery of many patients. For more than ten years, we have shared the vision that blood purification can significantly improve outcomes in critically ill patients. Together we have successfully expanded from sepsis into liver failure and other critical illnesses, and now organ transplantation. We look forward to many more years of continued progress and shared success." New Clinical Data and Scientific Leadership at ISICEM 2026 Today, CytoSorbents is hosting a featured symposium at ISICEM entitled: "Hemoadsorption as part of an individualized patient concept in Intensive Care – Key Learnings and Best Practices" Chair: Dr. Ricard Ferrer, Barcelona/Spain and Dr. Zsolt Molnar, Budapest/Hungary The importance of timing and dosing in different indications Dr. Gerd Klinkmann, Rostock/Germany Update on drug removal – we are on the safe side if we do it right Dr. Gabriella Bottari, Rome/Italy The new kid on the block – Cytokine Release Syndrome (CRS) after CAR-T cell therapy Dr. Peter Pickkers, Nijmegen/The Netherlands In addition, multiple abstracts and poster presentations presented at ISICEM further strengthen the clinical evidence base for CytoSorb therapy (click on title for full abstract): COSMOS Registry – Real-World Critical Care Outcomes (n=306, 23 sites, 6 countries) Significant reductions in vasopressor requirements, improved oxygenation, and fluid balance (all p<0.0001) ICU mortality of 32.7%, lower than predicted by severity scores 90-day survival of 56.5%, with >90% dialysis independence Rhabdomyolysis Substudy (n=45) Significant reduction in myoglobin levels (~8,800 → ~3,000 µg/L, p<0.0001) Improved kidney function markers 71% ICU survival; only 8% dialysis-dependent at 90 days Toxic Shock Syndrome Case Series (n=7) Rapid improvements in SOFA scores, lactate, and inflammatory biomarkers Shock reversal in 6 of 7 patients; 6 survivors to ICU discharge In Vitro Comparative Study CytoSorb demonstrated the strongest reduction of inflammatory cytokines versus competing hemoperfusion systems Competing systems showed limited efficacy or unfavorable inflammatory responses Meta-Analysis in COVID-19 (n=875) Trend toward reduced mortality (OR 0.74) No evidence of harm, supporting continued use in hyperinflammatory conditions "These data and clinical experiences continue to reinforce CytoSorb's role as a versatile, frontline blood purification therapy across a broad range of critical illnesses," added Dr. Chan. "Together with innovations like HotSwap™, we are making it easier for clinicians to deliver consistent, high-quality care to the sickest patients." About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorbents' lead product, CytoSorb ®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States. In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, VetResQ®, Purifi®, HotSwap™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, K+ontrol™, DrugSorb®, ContrastSorb, and others. For more information, please visit the Company's website at and follow us on Facebook and X and LinkedIn. Forward-Looking Statements This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve cash-flow break-even in the first quarter of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws. Please Click to Follow Us on Facebook and X U.S. Company Contact: Peter J. Mariani, Chief Financial Officer [email protected] Investor Relations Contacts: Aman Patel, CFA & Adanna G. Alexander, PhD ICR Healthcare [email protected] SOURCE Cytosorbents Corp 21% more press release views with Request a Demo

Drug Approval

19 Mar 2026

·www.businesswire.com

New Drug Cost Study: Canadian Online Pharmacies Offer Up to 89% Savings Versus GoodRx and Amazon for U.S. Consumers, Says Campaign for Personal Prescription Importation

HILLSBOROUGH, N.J.--(BUSINESS WIRE)--The Campaign for Personal Prescription Importation (CPPI), a non-profit advocate for affordable access to prescription medications, has released a new price comparison study highlighting the stark differences between U.S. and Canadian pharmacy prices for popular brand-name prescription drugs. We’re in an affordability epidemic. With the ability to personally import essentially identical medications from Canada, U.S. consumers can find desperately needed relief. Using data researched in Mar. 2026, CPPI’s analysis shows that for a sample of 10 popular, name-brand prescription medicines – all daily maintenance medications for common conditions – U.S. consumers can save 52% to 89% by purchasing from licensed Canadian online pharmacies. These results show personal importation from Canada continues to be a significant option for those facing exorbitantly high drug costs. America in a Drug “Affordability Epidemic” CPPI’s study underscores how U.S. prescription costs outpace affordability – as a great number of Americans are dangerously non-compliant with their drug therapy. For instance, a recent survey from the Kaiser Family Foundation (KFF) reveals that about one in five adults (21%) have not filled a prescription due to cost. Additionally, the KFF survey finds about one in seven adults say they have cut pills in half or skipped doses of medicine in the last year because of the cost. “These results highlight the ongoing need for easily accessible alternatives to notoriously high U.S. pharmaceutical prices. We’re in an affordability epidemic,” said CPPI’s Executive Director Ken Hunter. “Millions of Americans are on fixed incomes, have high-deductible health plans that skyrocketed in price when Affordable Care Act subsidies ended in December, or can’t afford insurance at all. With the ability to personally import essentially identical medications from Canada, consumers can find desperately needed relief.” CPPI’s findings, drawn from research comparing GoodRx and Amazon prices in the U.S. against Canadian equivalents, demonstrate average savings of over 64% across 10 commonly prescribed brand-name drugs. These include treatments for conditions including Type 2 diabetes, blood clots, and overactive bladder. Top savings examples for 90-day supplies include: Jublia (12 ml, antifungal): U.S. GoodRx price $2,236.00, U.S. Amazon price $2,502.10, Canadian pharmacy average $257.77 – 89% savings. Xifaxan (550 mg, treats IBS): U.S. GoodRx price $10,036.00, U.S. Amazon price $11,233.90, Canadian pharmacy average $2,325.78 – 78% savings. Myrbetriq (50 mg, treats overactive bladder): U.S. GoodRx price $1,129.00, U.S. Amazon price $994.78, Canadian pharmacy average $314.57 – 70% savings. Additional drugs researched in the study included Xarelto, Jardiance, Rybelsus, Farxiga, Trintellix, Premarin, and Eliquis. The full comparison chart of the 10 popular prescription medications is at https://shorturl.at/odDrW. "With U.S. drug prices being less affordable for millions, this study shows personal prescription importation from licensed Canadian pharmacies remains a proven lifeline that is available today," said Hunter. "Our data shows consumers can slash costs on essential brand-name medications, allowing them to prioritize health without financial ruin. This transforms lives, and Americans should know they have this safe, reliable option." For more information on safe importation and to join (for free) the fight for affordable medications, visit www.PersonalImportation.org. Methodology: Prices obtained Mar. 2026 for 90-day supplies. Amazon pricing is for delivery to N.J.; GoodRx pricing is from N.J. pharmacies using cash price with the lowest after-coupon discount price; Canadian mail-order pricing uses the average of a cross-section of pharmacies certified by Canadian International Pharmacy Assn. (CIPA.com) and is for Health Canada-approved, brand-name products dispensed by a pharmacy licensed in Canada. Savings based on average of GoodRx and Amazon prices. At time of survey, Rybelsus 7 mg was priced but unavailable at Amazon. All registered trademarks referred to herein belong to their respective owners. About CPPI: The Campaign for Personal Prescription Importation (CPPI), based in Hillsborough, N.J., is a national nonprofit patient advocacy organization fighting for Americans' access to safe, affordable prescription medications from Canada for personal use. Tens of millions of Americans – especially the elderly and others on fixed incomes – struggle to pay the extremely high prices of prescription medications in the U.S. CPPI is their voice. For more information and to join us: www.PersonalImportation.org.

16 Mar 2026

·www.fiercepharma.com

Bayer heads to regulators with nondiabetic kidney disease trial win for Kerendia

Bayer did not divulge fine details around Kerendia’s performance but noted that it plans to present new data at an upcoming medical conference and submit them to regulators in hopes of expanding Kerendia into the nondiabetic chronic kidney disease population. With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population of patients with chronic kidney disease (CKD). Kerendia, also known as finerenone, met the mark in Bayer’s late-stage Find-CKD study in adult patients with CKD who don’t have diabetes, allowing the study to hit its primary endpoint, the company said Monday. In the trial, Bayer’s drug helped patients chart a statistically significant and clinically meaningful reduction in kidney function decline compared to placebo, as measured by the estimated glomerular filtration rate (eGFR) slope, which is used as a surrogate endpoint for clinical kidney outcomes and a predictor for the risk of kidney failure. Patients in both trial arms received standard of care in addition to placebo or Kerendia.Bayer did not divulge fine details around Kerendia’s performance but noted that it plans to present the data at an upcoming medical conference and submit them to regulators in hopes of expanding Kerendia into the nondiabetic CKD population. Kerendia first emerged on the U.S. scene in 2021 with an FDA nod to curb the risk of kidney function decline, kidney failure, cardiovascular death, nonfatal heart attacks and hospitalization in patients with CKD associated with Type 2 diabetes. In addition, the mineralocorticoid receptor antagonist last year picked up a green light for two types of heart failure—either with preserved ejection fraction or mildly reduced ejection fraction—and has become, alongside Nubeqa, a key piece in Bayer’s strategy to navigate the decline of older products Xarelto and Eylea. Of the roughly 850 million people estimated to have CKD worldwide, “more than half” have nondiabetic CKD, according to Bayer. That version of the condition can stem from multiple sources, but the most common are hypertension and glomerulonephritis, with the latter referring to the inflammation of the tiny filters in the kidneys dubbed glomeruli, the company explained. Hypertension-linked CKD is the second most common cause of kidney failure, according to Bayer, which also noted that patients with the nondiabetic incarnation of the disease face a roughly 2.6 times higher risk of a fatal cardiovascular event than the general population without CKD. “The positive results of the Phase III FIND-CKD study represent an important advancement in the area of non-diabetic chronic kidney disease, regardless of the underlying cause,” Christian Rommel, global head of R&D at Bayer’s pharma division, said in a statement. Kerendia and its continued growth—both in terms of its sales and label—will be essential to Bayer’s execution in the coming months and years.The German conglomerate continues to grapple with generic competition against blood thinner Xarelto, which suffered (PDF) a 33% sales decline to 2.34 billion euros ($2.6 billion) last year, plus the recent entry of biosimilars to the Regeneron-partnered eye med Eylea, which experienced a 6% annual sales slide in 2025. The Eylea decline is expected to pick up pace in 2026, Bayer said in its earnings report earlier this month. Still, Kerendia and other newer drugs in Bayer’s roster are picking up steam. For all of last year, Kerendia’s sales soared a staggering 79%—and an even more impressive 93% in the fourth quarter specifically—to reach 829 million euros ($936 million) across 2025, coming close to but not quite breaching the blockbuster sales threshold. “We’re well set for our next wave of growth, right into the next decade, driven by significant, sustained Nubeqa and Kerendia sales,” Bayer’s pharma president Stefan Oelrich told analysts on a conference call in early March, highlighting the company’s fast-growing prostate cancer treatment alongside Kerendia.

Phase 3Clinical Result

100 Deals associated with Rivaroxaban

External Link

KEGG	Wiki	ATC	Drug Bank
D07086	Rivaroxaban	B01AF01	DB06228

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thromboembolism	Japan	Bayer Yakuhin Ltd.	24 Nov 2023
Thrombosis	United States	Janssen Pharmaceuticals, Inc.	20 Dec 2021
Atherosclerosis	European Union	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Iceland	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Liechtenstein	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Norway	Viatris Ltd. (New Zealand)	12 Nov 2021
Atrial Fibrillation	China	Bayer AG	31 Mar 2009
Myocardial Infarction	Australia	Bayer Australia Ltd.	24 Nov 2008
Recurrent deep vein thrombosis	Australia	Bayer Australia Ltd.	24 Nov 2008
Stroke	Australia	Bayer Australia Ltd.	24 Nov 2008
Systemic embolism	Australia	Bayer Australia Ltd.	24 Nov 2008
Acute Coronary Syndrome	European Union	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Iceland	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Liechtenstein	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Norway	Bayer AG	30 Sep 2008
Embolism	European Union	Bayer AG	30 Sep 2008
Embolism	Iceland	Bayer AG	30 Sep 2008
Embolism	Liechtenstein	Bayer AG	30 Sep 2008
Embolism	Norway	Bayer AG	30 Sep 2008
Peripheral arterial occlusive disease	European Union	Bayer AG	30 Sep 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	Australia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Belgium	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Canada	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	France	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Germany	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	India	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Malaysia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Nepal	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Saudi Arabia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Singapore	Bayer AG	18 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06901466 \| NCT07007143 (STAR-TEER, Pubmed \| Am Heart J)	Phase 4	Mitral Valve Insufficiency	1,912	Rivaroxaban plus clopidogrel (Requiring long-term OAC)	ktiyvfcsfy(fsymxoasnj) = enxrgdkflo tiscimjbje (tldcubcskm )	Positive	01 Jun 2026
				Aspirin plus clopidogrel (No OAC indication)	ktiyvfcsfy(fsymxoasnj) = jmuwrfpouf tiscimjbje (tldcubcskm )
NCT02504216 (VOYAGER-PAD, Pubmed \| Circ Cardiovasc Interv)	Phase 3	Peripheral Arterial Disease	6,564	Rivaroxaban 2.5 mg + Rivaroxaban 2.5 mg	lrcnlkjgio(lygfvbpybm) = ujqiezsreh cwjftesyxi (irralhdkxc )	Positive	27 Feb 2026
				Placebo + Aspirin 100 mg	lrcnlkjgio(lygfvbpybm) = kagypstevj cwjftesyxi (irralhdkxc )
NCT04724460 (ONCO PE, Pubmed \| J Am Heart Assoc)	Phase 4	Pulmonary Embolism	178	Rivaroxaban 18-month (PS=0)	gnpolffuft(ksoyldqupw) = omlnfilife rleabtgtcz (lglkdsjgdi ) View more	Positive	27 Feb 2026
				Rivaroxaban 6-month (PS≥1)	gnpolffuft(ksoyldqupw) = eungcavsrx rleabtgtcz (lglkdsjgdi ) View more
NCT05077683 (FRENCHIE, Pubmed \| JAMA Cardiol)	Phase 3	Thrombosis	560	DAPT plus rivaroxaban	mbgzafcpjs(qfsflzdfzz) = xwzsefzkvh ucwhqyaxur (xajbjkocql ) View more	Negative	25 Feb 2026
				DAPT	mbgzafcpjs(qfsflzdfzz) = virmevnqad ucwhqyaxur (xajbjkocql ) View more
NCT04990791 (WILLOW CCS, CTgov)	Phase 4	Angina, Unstable	48	Aspirin (Aspirin 75 mg Once a Day)	htokffsdvi(gqcmpoevgi) = vradvssczz gjcngiydvl (wprpaitclq, 0) View more	-	20 Feb 2026
				Rivaroxaban+Aspirin (Aspirin 75 mg Once a Day Plus Rivaroxaban 2.5 mg Twice Daily)	htokffsdvi(gqcmpoevgi) = vljtrerpjz gjcngiydvl (wprpaitclq, 217) View more
ASCO_GI2026	Not Applicable	Venous Thromboembolism	2,526	Apixaban	xwfttnvybv(oyljyqbquz): HR = 0.92 (95.0% CI, 0.81 - 1.06), P-Value = 0.257 View more	Positive	08 Jan 2026
				Rivaroxaban
PREVAPIX-ALL (ASH2025)	Not Applicable	-	19	DOAC	iuouaqnqrl(wjtdkdguiq) = upueqvjkae zhrhmygopj (qatwtunxub ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Atrial Fibrillation	32,294	Apixaban or Rivaroxaban with Amiodarone	efgtnnkutx(wzeqsbpofk) = nycqwkrhka kkaqyaekoc (jdzeiixxiw )	Positive	06 Dec 2025
				Apixaban or Rivaroxaban with Flecainide or Sotalol	efgtnnkutx(wzeqsbpofk) = hdmccfqoef kkaqyaekoc (jdzeiixxiw )
NCT02168829 (OCEAN, Pubmed \| N Engl J Med)	Phase 4	Atrial Fibrillation	1,284	Rivaroxaban 15 mg	afhrsjxvjc(spohpzomsa) = hfndhugrmw qmiuzwymad (duhrbajtly ) View more	Negative	08 Nov 2025
				Aspirin 70-120 mg	afhrsjxvjc(spohpzomsa) = ciibuuvgru qmiuzwymad (duhrbajtly ) View more
NCT02504216 (VOYAGER PAD, Pubmed \| J Am Heart Assoc)	Phase 3	Peripheral Arterial Disease	2,370	Rivaroxaban 2.5 mg	wobnxckbwt(hhzbqihmfy): win ratio = 1.16 (95.0% CI, 1.03 - 1.3), P-Value = 0.0167	Positive	04 Nov 2025
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rivaroxaban

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation